Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 22, 2025

Successful switch from pegcetacoplan to iptacopan after repeated severe breakthrough hemolysis events - case report.

View Full Paper
Ask AI
Bookmark
Share

Authors

WFWolfgang FürederARAndreas Reinisch

Discussion

Loading...

Member takes

Overview

Case report reveals effective switch to iptacopan after severe breakthrough hemolysis with pegcetacoplan, suggesting new treatment avenues.

Key Points

  • Switching to iptacopan led to no further breakthrough hemolysis episodes in the patient over 12 months.
  • The patient experienced severe breakthrough hemolysis and acute renal failure during pegcetacoplan treatment.
  • Swap to iptacopan reflected patient preference, yet achieved stable hemoglobin and reticulocyte counts.
  • Treatment highlights the potential for alternative therapies when pegcetacoplan fails to prevent hemolysis.

Cite This Study

Füreder et al. (2025) studied this question.

synapsesocial.com/papers/68d46fd431b076d99fa6a320https://doi.org/10.1080/16078454.2025.2559333
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria2026
  2. 2Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment2026
  3. 3Real-world breakthrough hemolysis patterns across 1,723 patient-years of complement inhibition in paroxysmal nocturnal hemoglobinuria2025
  4. 4Switching patients with PNH from pegcetacoplan to iptacopan: a case series2026
  5. 5Resolution of extravascular hemolysis with oral iptacopan monotherapy in a patient with treatment experienced paroxysmal nocturnal hemoglobinuria (PNH)2024 · 1 citations